ArticleFrontiers in microbiology2019
Piperacillin-Tazobactam (TZP) Resistance in
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Molecular pharmacodynamics of amoxicillin-clavulanic acid for urinary tract infections caused by Escherichia coli.Nature communications · 2026Article
- Shifts inMicrobiology spectrum · 2025Article
- A high-resolution genomic and phenotypic analysis of resistance evolution of anJournal of medical microbiology · 2025Article
- High Frequency of Detection of NDM-Producing Enterobacterales Among Companion Animals Hospitalized in an Italian Veterinary Teaching Hospital.Transboundary and emerging diseases · 2025Article
- Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Evaluation of pre-treated healthcare wastes during COVID-19 pandemic reveals pathogenic microbiota, antibiotics residues, and antibiotic resistance genes against beta-lactams.Environmental research · 2023Article
- Multidrug Resistance and Plasmid Profiles ofInternational journal of microbiology · 2023Article
- Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistantEmerging microbes & infections · 2022Article
- Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases.Antimicrobial agents and chemotherapy · 2022Article
- Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam inPolish journal of microbiology · 2022Article
- Piperacillin/tazobactam-resistant, cephalosporin-susceptibleMicrobial genomics · 2022Article
- Analysis of Antimicrobial Resistance in Non-typhoidalFrontiers in veterinary science · 2022Article
- Assessment of Phenotype Relevant Amino Acid Residues in TEM-β-Lactamases by Mathematical Modelling and Experimental Approval.Microorganisms · 2021Article
- Plasmid-Mediated Antibiotic ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Clinically RelevantMicroorganisms · 2021Article
- Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaNature communications · 2020Article
- Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.Antimicrobial agents and chemotherapy · 2020Article
- Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin-Tazobactam and Ceftolozane-Tazobactam in Tigecycline-Non-SusceptibleInfection and drug resistance · 2020Article
- Emergence of NDM-1- and CTX-M-3-ProducingFrontiers in microbiology · 2019Article
- Inoculation Pneumonia Caused by Coagulase NegativeFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TEM-1, mediated by plasmid and transposon, is the most commonly encountered β-lactamase in Gram-negative bacteria. Four different promoters upstream of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.